The findings in the paper imply that mitochondria may play an important role in brain resilience, and targeting mitochondria may open a new door to Alzheimer's Disease prevention and therapy.

This study identifies research trends and hotspots on the comorbidity between periodontitis and neurodegenerative diseases, incl. Alzheimer's.

The objective of this study was to assess the neuropsychological characteristics of individuals with early-onset Alzheimer's disease (EOAD), late-onset Alzheimer's disease (LOAD), and very-late-onset Alzheimer's disease (VLOAD). The findings indicate notable neuropsychological variations across different age groups, demonstrating a progressive decline in cognitive function with age rather than distinct clinical presentations.

This cross sectional study found that serum lipid levels were significantly correlated with lower-extremity function in participants with and without AD but not with gait disorder in participants with AD.

A meta-analysis of the relationship between sleep and β-Amyloid biomarkers in Alzheimer’s disease

Identify how hiPSC models can contribute to understanding Alzheimer's Disease-associated synaptic dysfunction and axonal loss

This study highlights that pomegranate supplementation can be a promising source of protection against Alzheimer's disease.

This paper concludes that it is imperative to identify effective, early treatments for Alzheimer's disease. Creatine is an important bioenergetic molecule, and the Creatine system is shown to be dysfunctional in the brain of individuals with Alzheimer's disease. Therefore, Ceatine may serve as a potential target for prevention and therapy and creatine monohydrate supplementation may be beneficial in Alzheimer's disease. To date, only rodent studies have investigated the use of creatine monohydrate as a treatment for Alzheimer's disease.. Thus, clinical trials investigating the effects of creatine monohydrateon cognition and creatine monohydrate’s mechanisms in humans with Alzheimer's disease as well as its potential as a strategy to prevent cognitive decline in those with normal cognition, are needed. There is much to be learned about CrM intervention and brain health in different life and disease phases.

PLCγ2 is genetically linked to Alzheimer’s disease (AD), but it is unclear how PLCγ2 contributes to pathology. Tsai et al. demonstrate that AD-associated PLCG2 variants bidirectionally orchestrate microglial responses to plaques and impact neural function in an AD mouse model. This positions PLCγ2 as a key microglial signaling node and shows that targeting PLCγ2 could have therapeutic benefits in AD.

Training interventions with psychodrama for formal caregivers of those with dementia